Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.
DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a Potential Biomarker To Predict the Risk of Psoriasis Patients in Developing Psoriatic Arthritis.
Chiu1, Yahui Grace, Shanmugarajah3, Sutha, Panepento1, Ben, Eder2, Lihi, Chandran2, Vinod, Gladman2, Dafna, Moorehead1, Sharon
20% of psoriasis (Ps) patients (pts) develop psoriatic arthritis (PsA) within 10 years of Ps onset. Identification of an arthritis biomarker in Ps pts would facilitate early intervention and possibly delay and/or prevent onset of PsA. Previously, we reported an increased frequency of circulating osteoclast precursors (OCP) in one third of Ps pts without arthritis. We hypothesized that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a transmembrane protein that is required for the fusion of monocytes during osteoclast (OC) formation, may serve as an arthritis susceptibility biomarker in Ps.
We previously identified 4 major DC-STAMP expression patterns in human PBMC with an anti-DC-STAMP antibody by flow cytometry. Most healthy controls have low OCP and show DC-STAMP pattern I, whereas PsA pts demonstrate elevated OCP and are more likely to manifest DC-STAMP pattern IV. We analyzed DC-STAMP expression patterns by flow cytometry and OCP frequency in cultured monocytes in a longitudinal cohort of 24 Ps pts. They were assessed by rheumatologists based on standard criteria and did not have PsA. They have been followed for 3 years on average.
Table 1 summarizes the baseline clinical features, DC-STAMP patterns and frequency of OC in 24 pts. Two, 6, 10, 6 Ps pts manifested DC-STAMP pattern I, II, III, and IV, respectively (column (a) & (b)). The OCP frequency (mean±standard deviation) is shown in column (c). Within 3 years, 2 pts developed PsA by the CASPAR criteria (column (f)). Their demographics and clinical variables are depicted in Table 2.
Data from this longitudinal cohort registry suggest that DC-STAMP is a potential marker to predict development of PsA in Ps pts. Two pts who developed PsA have DC-STAMP pattern III and pattern IV, the most common patterns seen in PsA pts. Additional studies are required to further define the potential of DC-STAMP as an arthritis susceptibility biomarker.
|(a) DC-STAMP Pattern||(b) # of subjects||(c) OCP frequency (per 106 monocytes)||(d) Average of age||(e) PASI score||(f) # of pts develop PsA|
|I||2||47 ± 25||62||4.6||0|
|II||6||279 ± 365||57||2.9||0|
|III||10||380 ± 398||49||8.2||1|
|IV||6||1063 ± 954||36||4.1||1|
|Subject||Gender||Age||DC-STAMP pattern||OC frequency (per 106 monocytes)||PASI score 3 years ago||PASI score after arthritis onset||Years from Ps to PsA|
To cite this abstract, please use the following information:
Chiu, Yahui Grace, Shanmugarajah, Sutha, Panepento, Ben, Eder, Lihi, Chandran, Vinod, Gladman, Dafna, et al; DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a Potential Biomarker To Predict the Risk of Psoriasis Patients in Developing Psoriatic Arthritis. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :521